Guidelines on the use and monitoring of heparin.

T. Baglin, T. W. Barrowcliffe, A. Cohen, Michael Greaves, British Committee for Standards in Haematology

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

The guideline group was selected to be representative of UK-based medical experts. The drafting group met and communicated by e-mail. Draft guidelines were revised by consensus. Since the initial guideline published by the British Committee for Standards in Haematology (BCSH; Colvin & Barrowcliffe, 1993) evidence-based guidelines on the use and monitoring of heparin have been included in the American College of Chest Physicians Consensus Conferences on Antithrombotic Therapy ( ACCP; Hirsh & Raschke, 2004) and the Scottish Intercollegiate Guidelines Network ( SIGN; http://www.sign.ac.uk/guidelines/fulltext/36/section12.html). Reference to these guidelines is advised for a comprehensive review of the evidence. The recommendations in this BCSH guideline generally reflect those of the ACCP and SIGN and are updated where appropriate to encompass recent studies. The guideline was reviewed by a multidisciplinary sounding board, the BCSH and the British Society for Haematology (BSH) and comments incorporated where appropriate. Criteria used to quote levels and grades of evidence are as in Appendix 3 of the Procedure for Guidelines Commissioned by the BCSH (http://www.bcshguidelines.com).

The target audience for this guideline is healthcare professionals involved in the management of patients receiving heparin.

Original languageEnglish
Pages (from-to)19-34
Number of pages15
JournalBritish Journal of Haematology
Volume133
Issue number1
DOIs
Publication statusPublished - Apr 2006

Keywords

  • heparin
  • guideline
  • low-molecular weight heparin
  • LOW-MOLECULAR-WEIGHT
  • DEEP-VEIN THROMBOSIS
  • ACUTE ISCHEMIC STROKE
  • INTRAVENOUS UNFRACTIONATED HEPARIN
  • PARTIAL THROMBOPLASTIN TIME
  • FATAL PULMONARY-EMBOLISM
  • PLACEBO-CONTROLLED TRIAL
  • RECOMBINANT FACTOR VIIA
  • HIP FRACTURE SURGERY
  • ANTI-XA ACTIVITY

Cite this

Baglin, T., Barrowcliffe, T. W., Cohen, A., Greaves, M., & British Committee for Standards in Haematology (2006). Guidelines on the use and monitoring of heparin. British Journal of Haematology, 133(1), 19-34. https://doi.org/10.1111/j.1365-2141.2005.05953.x

Guidelines on the use and monitoring of heparin. / Baglin, T.; Barrowcliffe, T. W.; Cohen, A.; Greaves, Michael; British Committee for Standards in Haematology.

In: British Journal of Haematology, Vol. 133, No. 1, 04.2006, p. 19-34.

Research output: Contribution to journalArticle

Baglin, T, Barrowcliffe, TW, Cohen, A, Greaves, M & British Committee for Standards in Haematology 2006, 'Guidelines on the use and monitoring of heparin.', British Journal of Haematology, vol. 133, no. 1, pp. 19-34. https://doi.org/10.1111/j.1365-2141.2005.05953.x
Baglin T, Barrowcliffe TW, Cohen A, Greaves M, British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin. British Journal of Haematology. 2006 Apr;133(1):19-34. https://doi.org/10.1111/j.1365-2141.2005.05953.x
Baglin, T. ; Barrowcliffe, T. W. ; Cohen, A. ; Greaves, Michael ; British Committee for Standards in Haematology. / Guidelines on the use and monitoring of heparin. In: British Journal of Haematology. 2006 ; Vol. 133, No. 1. pp. 19-34.
@article{7ace471aff784a7cadde2de7bbe7f098,
title = "Guidelines on the use and monitoring of heparin.",
abstract = "The guideline group was selected to be representative of UK-based medical experts. The drafting group met and communicated by e-mail. Draft guidelines were revised by consensus. Since the initial guideline published by the British Committee for Standards in Haematology (BCSH; Colvin & Barrowcliffe, 1993) evidence-based guidelines on the use and monitoring of heparin have been included in the American College of Chest Physicians Consensus Conferences on Antithrombotic Therapy ( ACCP; Hirsh & Raschke, 2004) and the Scottish Intercollegiate Guidelines Network ( SIGN; http://www.sign.ac.uk/guidelines/fulltext/36/section12.html). Reference to these guidelines is advised for a comprehensive review of the evidence. The recommendations in this BCSH guideline generally reflect those of the ACCP and SIGN and are updated where appropriate to encompass recent studies. The guideline was reviewed by a multidisciplinary sounding board, the BCSH and the British Society for Haematology (BSH) and comments incorporated where appropriate. Criteria used to quote levels and grades of evidence are as in Appendix 3 of the Procedure for Guidelines Commissioned by the BCSH (http://www.bcshguidelines.com).The target audience for this guideline is healthcare professionals involved in the management of patients receiving heparin.",
keywords = "heparin, guideline, low-molecular weight heparin, LOW-MOLECULAR-WEIGHT, DEEP-VEIN THROMBOSIS, ACUTE ISCHEMIC STROKE, INTRAVENOUS UNFRACTIONATED HEPARIN, PARTIAL THROMBOPLASTIN TIME, FATAL PULMONARY-EMBOLISM, PLACEBO-CONTROLLED TRIAL, RECOMBINANT FACTOR VIIA, HIP FRACTURE SURGERY, ANTI-XA ACTIVITY",
author = "T. Baglin and Barrowcliffe, {T. W.} and A. Cohen and Michael Greaves and {British Committee for Standards in Haematology}",
year = "2006",
month = "4",
doi = "10.1111/j.1365-2141.2005.05953.x",
language = "English",
volume = "133",
pages = "19--34",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Guidelines on the use and monitoring of heparin.

AU - Baglin, T.

AU - Barrowcliffe, T. W.

AU - Cohen, A.

AU - Greaves, Michael

AU - British Committee for Standards in Haematology

PY - 2006/4

Y1 - 2006/4

N2 - The guideline group was selected to be representative of UK-based medical experts. The drafting group met and communicated by e-mail. Draft guidelines were revised by consensus. Since the initial guideline published by the British Committee for Standards in Haematology (BCSH; Colvin & Barrowcliffe, 1993) evidence-based guidelines on the use and monitoring of heparin have been included in the American College of Chest Physicians Consensus Conferences on Antithrombotic Therapy ( ACCP; Hirsh & Raschke, 2004) and the Scottish Intercollegiate Guidelines Network ( SIGN; http://www.sign.ac.uk/guidelines/fulltext/36/section12.html). Reference to these guidelines is advised for a comprehensive review of the evidence. The recommendations in this BCSH guideline generally reflect those of the ACCP and SIGN and are updated where appropriate to encompass recent studies. The guideline was reviewed by a multidisciplinary sounding board, the BCSH and the British Society for Haematology (BSH) and comments incorporated where appropriate. Criteria used to quote levels and grades of evidence are as in Appendix 3 of the Procedure for Guidelines Commissioned by the BCSH (http://www.bcshguidelines.com).The target audience for this guideline is healthcare professionals involved in the management of patients receiving heparin.

AB - The guideline group was selected to be representative of UK-based medical experts. The drafting group met and communicated by e-mail. Draft guidelines were revised by consensus. Since the initial guideline published by the British Committee for Standards in Haematology (BCSH; Colvin & Barrowcliffe, 1993) evidence-based guidelines on the use and monitoring of heparin have been included in the American College of Chest Physicians Consensus Conferences on Antithrombotic Therapy ( ACCP; Hirsh & Raschke, 2004) and the Scottish Intercollegiate Guidelines Network ( SIGN; http://www.sign.ac.uk/guidelines/fulltext/36/section12.html). Reference to these guidelines is advised for a comprehensive review of the evidence. The recommendations in this BCSH guideline generally reflect those of the ACCP and SIGN and are updated where appropriate to encompass recent studies. The guideline was reviewed by a multidisciplinary sounding board, the BCSH and the British Society for Haematology (BSH) and comments incorporated where appropriate. Criteria used to quote levels and grades of evidence are as in Appendix 3 of the Procedure for Guidelines Commissioned by the BCSH (http://www.bcshguidelines.com).The target audience for this guideline is healthcare professionals involved in the management of patients receiving heparin.

KW - heparin

KW - guideline

KW - low-molecular weight heparin

KW - LOW-MOLECULAR-WEIGHT

KW - DEEP-VEIN THROMBOSIS

KW - ACUTE ISCHEMIC STROKE

KW - INTRAVENOUS UNFRACTIONATED HEPARIN

KW - PARTIAL THROMBOPLASTIN TIME

KW - FATAL PULMONARY-EMBOLISM

KW - PLACEBO-CONTROLLED TRIAL

KW - RECOMBINANT FACTOR VIIA

KW - HIP FRACTURE SURGERY

KW - ANTI-XA ACTIVITY

U2 - 10.1111/j.1365-2141.2005.05953.x

DO - 10.1111/j.1365-2141.2005.05953.x

M3 - Article

VL - 133

SP - 19

EP - 34

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -